
Mettler-Toledo International MTD
$ 1 082.63
3.03%
Quarterly report 2026-Q1
added 05-08-2026
Mettler-Toledo International Gross Profit 2011-2026 | MTD
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Mettler-Toledo International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.39 B | 2.33 B | 2.24 B | 2.31 B | 2.17 B | 1.8 B | 1.74 B | 1.68 B | 1.57 B | 1.44 B | 1.35 B | 1.36 B | 1.28 B | 1.24 B | 1.22 B | 1.04 B | 889 M | 993 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.39 B | 889 M | 1.61 B |
Quarterly Gross Profit Mettler-Toledo International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 556 M | 609 M | 580 M | 526 M | - | 572 M | 566 M | 548 M | - | 560 M | 584 M | 547 M | - | 585 M | 572 M | 520 M | - | 556 M | 537 M | 472 M | 559 M | 470 M | 398 M | 374 M | 498 M | 435 M | 420 M | 388 M | 478 M | 419 M | 413 M | 375 M | 456 M | 401 M | 376 M | 343 M | 419 M | 369 M | 348 M | 300 M | 391 M | 340 M | 323 M | 299 M | 394 M | 344 M | 328 M | 293 M | 375 M | 319 M | 309 M | 279 M | 357 M | 308 M | 299 M | 277 M | 346 M | 308 M | 299 M | 277 M | 256 M | 247 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 609 M | 247 M | 415 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 19.72 | 2.71 % | $ 572 M | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 16.36 | 2.57 % | $ 495 M | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 114.94 | 1.22 % | $ 9.48 B | ||
|
Agilent Technologies
A
|
2.84 B | $ 113.33 | 2.5 % | $ 34.5 B | ||
|
Interpace Biosciences
IDXG
|
24.1 M | $ 1.8 | - | $ 7.96 M | ||
|
Co-Diagnostics
CODX
|
400 K | $ 2.31 | 17.26 % | $ 3.07 M | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Illumina
ILMN
|
2.86 B | $ 141.35 | -0.24 % | $ 22.5 B | ||
|
Aspira Women's Health
AWH
|
5.92 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Guardant Health
GH
|
144 M | $ 113.24 | 15.33 % | $ 14.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 21.1 | 2.78 % | $ 1.12 B | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 96.33 | 3.7 % | $ 6.5 B | ||
|
Medpace Holdings
MEDP
|
246 M | $ 421.05 | 0.27 % | $ 12.1 B | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
National Research Corporation
NRC
|
81.5 M | $ 19.2 | 2.4 % | $ 430 M | ||
|
Natera
NTRA
|
127 M | $ 202.96 | 3.53 % | $ 20 B | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 156.38 | 2.59 % | $ 7.75 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Personalis
PSNL
|
22.1 M | $ 7.86 | 11.58 % | $ 701 M | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
NeoGenomics
NEO
|
314 M | $ 8.79 | 4.77 % | $ 1.13 B | ||
|
Exact Sciences Corporation
EXAS
|
2.26 B | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
577 M | $ 3.74 | 5.21 % | $ 346 M | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 26.76 | 2.71 % | $ 25.4 B | ||
|
Thermo Fisher Scientific
TMO
|
11.3 B | $ 449.72 | 0.43 % | $ 170 B | ||
|
Senseonics Holdings
SENS
|
15.8 M | $ 5.69 | 2.62 % | $ 237 M | ||
|
Twist Bioscience Corporation
TWST
|
6.96 M | $ 54.25 | 9.6 % | $ 3.24 B | ||
|
QIAGEN N.V.
QGEN
|
1.3 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
-58.5 K | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
498 K | $ 2.35 | -1.26 % | $ 5.4 M | ||
|
Trinity Biotech plc
TRIB
|
21.4 M | $ 0.6 | 6.65 % | $ 216 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 257.11 | 1.35 % | $ 21.4 B | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
1.4 B | $ 341.81 | 2.57 % | $ 20.4 B | ||
|
Neogen Corporation
NEOG
|
421 M | $ 8.73 | 4.49 % | $ 1.89 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 193.73 | 1.75 % | $ 21.5 B |